Friday 12 December 2025
  • About
  • Contact
  • Login
  • VC & Investment
  • M&A
  • AI
  • Podcasts
  • News
    • Pharmaceutical News
    • Biotechnology News
    • Generics News
    • Biosimilars news
    • In Brief
    • Legal
    • Company Pages
    • In The Boardroom
  • Insights
    • Analysis
    • Special Report
    • Interviews
    • Expert View
    • From Our Correspondent
    • One To Watch Companies
    • Digital Pharma
    • Pharma Leaders
  • Regulatory
    • FDA
    • EMA
    • Pricing, Reimbursement and Access
    • Regulation
    • Government Affairs
    • Trump Administration
  • Therapy Areas
    • Dermatologicals
    • Oncology
    • Neurological
    • Rare Diseases
    • Hematology
    • Cardio Vascular
    • Diabetes
    • Cell And Gene Therapy
  • Conferences
    • JPM Healthcare Conference
    • ESMO
    • ASCO
    • ASH
    • EULAR
    • AAIC
    • EASD
    • Forthcoming Events
  • Ones to Watch
  • About
  • Contact
  • Newsletter
  • Sign inSubscribe
Subscribe
  • Home
  • California stem cell funding gets legal OK

California stem cell funding gets legal OK

27 May 2007

The Supreme Court of the US State of California has effectively authorized funding of stem cell research by the state government, which means that plans for the California Institute of Regenerative Medicine to issue $250.0 million in bonds can now go ahead.

Opponents had hoped to demonstrate that the funding, approved by a November 2004 popular referendum in the state, was unconstitutional under California law. Proposition 71 was carried with 59% support.

Robert Klein, the CIRM's governing committee chairman, told the San Francisco Chronicle that the first $250.0 million bond issue would take place by the end of August and would mostly reimburse state and private donor loans which supported the Institute during the legal dispute. A further bond issue could bring the research center's total borrowing to $300.0 million by the end of year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Try before you buy

 

Free

7 day trial access

Take a Free Trial
  • All the news that moves the needle in pharma and biotech
  • Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
  • Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





More ones to watch >


Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news






Today's issue

MHRA approves Ezmekly to treat plexiform neurofibromas
Pharmaceutical
MHRA approves Ezmekly to treat plexiform neurofibromas
12 December 2025
Pharmaceutical
Lilly shares rise on retatrutide weight loss data
12 December 2025
Biotechnology
Prolynx bags $70 million to advance obesity candidates; names CEO
12 December 2025
Generics
Gaelic Laboratories buys Athlone to scale Irish beta-lactam manufacturing
12 December 2025
Pharmaceutical
EMA backs political deal on sweeping EU pharmaceutical reform
12 December 2025
Biotechnology
Amgen wins FDA approval for Uplizna in generalized myasthenia gravis
12 December 2025
Pharmaceutical
IQVIA Digital Health trends report
12 December 2025

Company Spotlight

Ginkgo Bioworks
Ginkgo Bioworks is headquartered in Boston, Massachusetts, where it operates its central “Foundry” for high-throughput cell engineering. The company supports partners globally across biopharma, agriculture, industrial biotechnology, and biosecurity through its Boston-based infrastructure and distributed digital platforms.




The Pharma Letter

39-43 Putney High Street, Putney
London, SW15 1SP
United Kingdom

  • About us
  • Contact
  • Subscribe
  • Sponsorship/advertising


  • Terms and Conditions
  • Privacy Policy
  • Twitter
  • Linkedin

Copyright © The Pharma Letter 2025   |   Headless Content Management with Blaze